{"nctId":"NCT02974907","briefTitle":"Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2","startDateStruct":{"date":"2016-11","type":"ACTUAL"},"conditions":["Dry Eye Syndrome"],"count":601,"armGroups":[{"label":"RGN-259","type":"EXPERIMENTAL","interventionNames":["Drug: RGN-259"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"RGN-259","otherNames":["Tβ4","Thymosin Beta 4"]},{"name":"Placebo","otherNames":["Vehicle Control"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Be at least 18 years of age;\n* Provide written informed consent;\n* Have a subject reported history of dry eye for at least 6 months\n* Have a history of use or desire to use eye drops for dry eye symptoms within 6 months\n\nExclusion Criteria:\n\n* Have any clinically significant slit-lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;\n* Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;\n* Have ab uncontrolled systemic disease:","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ocular Discomfort","description":"Change from Baseline at Day 29 using the Ora Calibra® Ocular Discomfort Scale (6-point scale where 0 = none and 5 = worst)","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":null},{"groupId":"OG001","value":"-0.04","spread":null}]}]}]},{"type":"PRIMARY","title":"Corneal Fluorescein Staining","description":"Change from Baseline at Day 29 using the Ora Calibra® scale (5-point scale with half (0.5) increments where 0 = none and 4 = severe)","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":null},{"groupId":"OG001","value":"-0.01","spread":null}]}]}]},{"type":"SECONDARY","title":"Corneal Fluorescein Staining","description":"Comparing each of active group \\& Placebo.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Unanesthetized Schirmer's Test","description":"Comparing each of active group \\& Placebo.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Ocular Surface Disease Index (OSDI)©","description":"Comparing each of active group \\& Placebo.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Tear Film Break-Up Time","description":"Comparing each of active group \\& Placebo.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Visual Acuity","description":"Change or shifts from Baseline","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Biomicroscopy Using the Slit-lamp","description":"Change or shifts from Baseline","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Adverse Event Query","description":"Frequencies","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Biomicroscopy Using the Undilated Fundoscopy","description":"Change or shifts from Baseline","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":299},"commonTop":["Nasopharyngitis","Visual Acuity Reduced","Sinusitis","Eye Pain","Upper Respiratory Tract Infection"]}}}